-- Conference Call on Friday, May 16, 2008 at 9:00 a.m. ET -- BEIJING, May 16
BEIJING, May 16 /Xinhua-PRNewswire/ -- Sinovac Biotech Ltd. (Amex: SVA), a
leading developer and provider of vaccines in China, today announced the
Company's unaudited interim consolidated financial statements for the
three-month period ended March 31, 2008.
First Quarter Highlights
-- Sales increased 123% year-over-year to $8.9 million
-- Sold 1.5 million doses of Healive(R), up 113%
-- Gross profit grew 135% year-over-year to $7.8 million, with 88% gross
margin
-- Operating income rose 116% year-over-year to $3.1 million
-- Net income increased to $1.6 million
-- Diluted EPS grew 100% to $0.04
-- Completed $9.75 million private placement
Mr. Weidong Yin, Chairman, President and CEO, commented, "Our first
quarter sales demonstrate the continued execution of our commercialization
strategy. We were pleased with the 123% increase in quarterly sales. We
continue to experience robust Healive(R) sales due to favorable market
development trends in China."
Mr. Yin continued, "We are pleased with the continued clinical advancement
of our pandemic influenza vaccine formulations. In early April, we received a
production license from the SFDA to exclusively supply Panflu(TM), our whole
viron H5N1 pandemic influenza vaccine, to the national stockpiling program.
Recently, we successfully completed Phase I trials for the split vaccine and
intend to commence the Phase II trials during the second quarter of 2008."
Three Months Ended March 31, 2008
For the first quarter 2008, sales increased 123% to $8.9 million, compared
to $4.0 million in the first quarter 2007. The growth was driven by higher
sales of Healive(R) with further market.
Gross profit for first quarter of 2008 was $7.8 million, with a gross
margin of 88.2%, compared to $3.3 million and 83.9%, respectively, for the
same period of 2007. The higher gross margin resulted from the increased
economies of scale and lower average unit costs associated with Healive(R)
production.
Total operating expenses for the first quarter of 2008 increased to $4.7
million, compared to $1.9 million in the same period of 2007. Selling, general
and administrative expenses for first quarter of 2008 were $3.6 million,
compared to $1.3 million in the same period of 2007. The year-over-year
increase in SG&A expenses reflected Sinovac's extensive promotion campaign for
Healive(R), and the recruiting of additional employees for the production,
quality control, sales, and marketing segments to position the Company for
market growth.
The aggregated research and development expenses for the first quarter of
2008 were $933,000 compared to $477,000 in the same period of 2007. Our net
R&D expenses were $929,000 for the first quarter of 2008, compared to $444,000
in the same period of 2007. The R&D expenses recognized as a reduction to
government grants were $4,000 in the first quarter of 2008, compared to
$33,000 in the same period of 2007.
Operating income was $3.1 million for the first quarter of 2008, compared
to $1.5 million in the same period of 2007. The year-over-year increase in
operating income reflected the significant increase in vaccine sales and the
moderately higher operating expenses.
Net income for the first quarter of 2008 was $1.6 million, or $0.04 per
diluted share, compared to $776,000, or $0.02 per diluted share, in the same
period of 2007. Net income for the first quarter of 2008 included $158,000 of
interest and financing expenses, $719,000 of income taxes, and $739,000 of
minority interest. Net income for the same period of 2007 included $86,000 of
interest and financing expenses, $342,000 of income taxes, and $310,000 of
minority interest.
As of March 31, 2008, Sinovac's cash and cash equivalents totaled $20.6
million, compared to $17.1 million as of December 31, 2007.
Sales and Marketing
During the first quarter of 2008, Sinovac sold approximately 1.5 million
doses of Healive(R), up from 0.7 million doses for the same period of 2007.
Higher sales in the first quarter of 2008 resulted from Healive promotion
campaign targeting the private market. During the first quarter of 2008,
Sinovac sold 31,000 doses of Bilive(R) and 24,000 doses seasonal flu vaccine.
Research and Development
In April 2008, Sinovac was granted a production license for Panflu(TM) by
the China State Food and Drug Administration (SFDA). PanfluTM is the first and
only approved vaccine available in China against the H5N1 influenza virus.
Under the production license for Panflu(TM) granted by SFDA, the vaccine is
solely approved for production to be supplied to the Chinese national vaccine
stockpiling program and will not be sold directly to the market.
Sinovac has successfully completed the Phase I clinical trials for its
split pandemic influenza vaccine.
The Phase I trial for the split pandemic influenza vaccine was conducted
by the Beijing Centers for Disease Control and Prevention, located in Huai Rou,
Beijing. The trial enrolled 160 volunteers from 3 to 70 years old, sorted into
four different age groups, who received doses of 5ug, 10ug, 15ug or 30ug and
were followed for an observation period. There were no serious adverse events.
Sinovac is on track to commence a Phase II trial of the split pandemic
influenza vaccine in the second quarter of 2008. The trial will include 350
volunteers covering three different age groups, namely children, adults and
elderly, to further assess the immunogenicity and safety of the vaccine as
well as determine vaccination dosage.
Conference Call Details
The Company will host a conference call on Friday, May 16, 2008 at 9:00
a.m. ET (9:00 p.m. Beijing time). To access the conference call, please dial
1-877-407-4018 (USA) or 1-201-689-8471 (international). A replay of the call
will be available from 11:00 a.m. ET on May 16, until May 30, 2008 at midnight.
To access the replay, please dial 1-877-660-6853 (USA) or 1-201-612-7415
(international) and reference the account number 3055 and the access code
285507. A live audio webcast of the call will also be available from the
Investors section on the corporate web site at http://www.sinovac.com . A
webcast replay can be accessed on the corporate website beginning May 16, 2008
and the replay will remain available for 30 days.
About Sinovac
Sinovac Biotech Ltd. is a China-based biopharmaceutical company that
focuses on the research, development, manufacture and commercialization of
vaccines that protect against human infectious diseases. Sinovac's
commercialized vaccines include Healive(R) (hepatitis A), Bilive(R) (combined
hepatitis A and B), Anflu(R) (influenza) and Panflu(TM) (H5N1). Sinovac is
currently developing universal pandemic influenza vaccine and Japanese
encephalitis vaccine. Additional information about Sinovac is available on its
website, http://www.sinovac.com . To be added to our distribution list, please
email: info@sinovac.com.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements
are made under the "safe harbor" provisions of the U.S. Private Securities
Litigation Reform Act of 1995. These forward-looking statements can be
identified by words or phrases such as "will," "expects," "anticipates,"
"future," "intends," "plans," "believes," "estimates" and similar statements.
Among other things, the business outlook and quotations from management in
this press release contain forward-looking statements. Statements that are not
historical facts, including statements about Sinovac's beliefs and
expectations, are forward-looking statements. Forward-looking statements
involve inherent risks and uncertainties. A number of important factors could
cause actual results to differ materially from those contained in any
forward-looking statement. Sinovac does not undertake any obligation to update
any forward-looking statement, except as required under applicable law.
SINOVAC BIOTECH LTD.
Consolidated Statements of Income and Comprehensive Income
Three Months Ended March 31, 2008 and 2007
(Unaudited)
(Expressed in U.S. Dollars)
20082007
Sales $8,862,001 $3,973,052
Cost of sales - (exclusive of depreciation
of land-use rights and amortization of
licenses and permits of $99,834 (2007 -
$92,728) 1,047,866 641,450
Gross profit 7,814,135 3,331,602
Selling, general and administrative
expenses 3,577,886 1,268,544
Research and development expenses - net
of $4,019 (2007 - $33,175) in government
research grants 929,336 443,745
Depreciation of property, plant and
equipment and amortization of licenses and
permits 178,229 169,041
Total operating expenses 4,685,451 1,881,330
Operating income 3,128,684 1,450,272
Interest and financing expenses (157,707)(86,056)
Interest and other income 46,350 64,024
Income before income taxes and minority
interest 3,017,327 1,428,240
Income tax expenses
- Current 645,335 290,219
- Deferred 73,181 51,735
Income before minority interest2,298,811 1,086,286
Minority interest share of income738,855 309,915
Net income for the period $1,559,956$776,371
Other comprehensive income
Cumulative translation adjustment $1,282,528$180,423
Comprehensive income $2,842,484$956,794
Earnings per share - basic and diluted $0.04 $0.02
Weighted average number of shares of
Common stock outstanding
- Basic41,088,322 40,199,948
- Diluted 41,470,579 40,524,360
SINOVAC BIOTECH LTD.
Consolidated Balance Sheets
(Unaudited)
(Expressed in U.S. Dollars)
March 31, 2008 December 31, 2007
ASSETS
Current assets
Cash and cash equivalents $20,578,712$17,071,497
Accounts receivable - net 21,289,266 16,983,892
Inventories 5,382,776 3,745,957
Prepaid expenses and deposits 566,869800,840
Deferred tax assets605,817579,703
Total current assets 48,423,440 39,181,889
Restricted cash1,401,510846
Property, plant and equipment 17,474,369 15,879,391
Long-term prepaid expenses and
deposits248,697298,731
Deferred tax asset 593,757693,053
Licenses and permits 1,355,097 1,394,052
Total assets $69,496,870$57,447,962
LIABILITIES AND STOCKHOLDERS'
EQUITY
Current liabilities
Loans payable $7,120,276 $6,836,110
Accounts payable and accrued
liabilities10,528,253 9,522,818
Due to related parties 46,971 46,971
Dividends payable to minority
interest of Sinovac Beijing 112,909 3,000,458
Deferred research grants 1,077,452 1,038,396
Total current liabilities 18,885,861 20,447,754
Deferred government grants 2,848,110 2,734,444
Loan Payable 1,424,055 1,367,222
Long - term debt 4,272,165 4,101,666
Total liabilities 23,158,026 24,546,420
Minority interest 3,662,570 2,897,687
Commitments and contingencies
STOCKHOLDERS' EQUITY
Preferred stock -- --
Authorized 50,000,000 shares at
par value of $0.001 each
Issued and outstanding: nil
Common stock 42,813 40,305
Authorized: 100,000,000 shares
at par value of $0.001 each
Issued and outstanding:
42,813,028 (2007 - 40,305,028 )
Subscriptions received61,990 9,170
Additional paid in capital41,884,604 32,109,997
Accumulated other comprehensive
income3,238,984 1,956,456
Dedicated reserves 2,999,396 2,999,396
Accumulated deficit (5,551,513) (7,111,469)
Total stockholders' equity42,676,274 30,003,855
Total liabilities and
stockholders' equity$69,496,870$$57,447,962
For more information, please contact:
Contact Information: Investors/Media:
Helen G. Yang Stephanie Carrington/Janine McCargo
Sinovac Biotech Ltd. The Ruth Group
Tel: +86-10-8289-0088 x871 Tel: +1-646-536-7017/7033
Fax: +86-10-6296-6910 Email: scarrington@theruthgroup.com
Email: info@sinovac.com jmccargo@theruthgroup.com
SOURCE Sinovac Biotech Ltd.
